MX390763B - Compuestos de tetraciclina - Google Patents

Compuestos de tetraciclina

Info

Publication number
MX390763B
MX390763B MX2019004452A MX2019004452A MX390763B MX 390763 B MX390763 B MX 390763B MX 2019004452 A MX2019004452 A MX 2019004452A MX 2019004452 A MX2019004452 A MX 2019004452A MX 390763 B MX390763 B MX 390763B
Authority
MX
Mexico
Prior art keywords
structural formula
tetracycline compounds
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Application number
MX2019004452A
Other languages
English (en)
Inventor
Cuixiang Sun
Diana Katharine Hunt
Magnus Ronn
Minsheng He
Roger B Clark
Wu- Yan ZHANG
Xiao- Yi Xiao
Original Assignee
Tetraphase Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetraphase Pharmaceuticals Inc filed Critical Tetraphase Pharmaceuticals Inc
Publication of MX390763B publication Critical patent/MX390763B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto representado por la Fórmula Estructural (I)(ver formula) (I), o una sal farmacéuticamente aceptable del mismo. Las variables para la Fórmula Estructural (I) se definen en el presente documento. También se describe una composición farmacéutica que comprende el compuesto de Fórmula Estructural (I), o una sal farmacéuticamente aceptable del mismo, y su uso terapéutico.
MX2019004452A 2012-08-31 2013-08-30 Compuestos de tetraciclina MX390763B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695947P 2012-08-31 2012-08-31
PCT/US2013/057690 WO2014036502A2 (en) 2012-08-31 2013-08-30 Tetracycline compounds

Publications (1)

Publication Number Publication Date
MX390763B true MX390763B (es) 2025-03-21

Family

ID=49170898

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015002657A MX364400B (es) 2012-08-31 2013-08-30 Compuestos de tetraciclina.
MX2019004452A MX390763B (es) 2012-08-31 2013-08-30 Compuestos de tetraciclina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015002657A MX364400B (es) 2012-08-31 2013-08-30 Compuestos de tetraciclina.

Country Status (27)

Country Link
US (3) US9573895B2 (es)
EP (2) EP2890673B1 (es)
JP (2) JP6301335B2 (es)
KR (2) KR102295673B1 (es)
CN (3) CN108276404A (es)
AU (3) AU2013308504B2 (es)
BR (1) BR112015004523B1 (es)
CA (1) CA2883238C (es)
CY (1) CY1122744T1 (es)
DK (1) DK2890673T3 (es)
EA (2) EA031523B1 (es)
ES (1) ES2712476T3 (es)
HR (1) HRP20190268T1 (es)
HU (1) HUE042600T2 (es)
IL (2) IL237437B (es)
LT (1) LT2890673T (es)
ME (1) ME03329B (es)
MX (2) MX364400B (es)
NZ (3) NZ705849A (es)
PL (1) PL2890673T3 (es)
PT (1) PT2890673T (es)
RS (1) RS58572B1 (es)
SG (2) SG10201801703RA (es)
SI (1) SI2890673T1 (es)
SM (1) SMT201900096T1 (es)
TR (1) TR201902057T4 (es)
WO (1) WO2014036502A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105367440A (zh) 2008-08-08 2016-03-02 四相制药公司 C7-氟取代的四环素化合物
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
HUE037852T2 (hu) 2009-08-28 2018-09-28 Tetraphase Pharmaceuticals Inc Tetraciklin-vegyületek
EA031523B1 (ru) * 2012-08-31 2019-01-31 Тетрафейз Фармасьютикалс, Инк. Тетрациклиновые соединения
JP7184756B6 (ja) * 2016-08-30 2022-12-20 テトラフェース ファーマシューティカルズ，インコーポレイテッド テトラサイクリン化合物および処置方法
HRP20240605T1 (hr) 2016-10-19 2024-07-19 Tetraphase Pharmaceuticals, Inc. Kristalni oblici eravaciklina
AU2019309435A1 (en) 2018-07-27 2021-01-21 Sandoz Ag Process for preparing rapidly or very rapidly dissolving tablets comprising freely soluble API
CN113444070A (zh) * 2021-07-28 2021-09-28 深圳市真味生物科技有限公司 一种由手性叔丁基亚磺酰胺合成手性尼古丁的制备方法
CN115448849B (zh) * 2022-11-10 2023-02-03 苏州富士莱医药股份有限公司 一种2-苄氧基-3-二苄基氨基-5-氟-6-甲基苯甲酸苯酯的制备方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639292A (es)
GB935384A (en) * 1959-03-30 1963-08-28 Pfizer & Co C Tetracycline derivatives and preparation thereof
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
GB1034933A (en) * 1962-10-29 1966-07-06 American Cyanamid Co 4-demethylamino-4-substituted amino 6-demethyl tetracyclines
US3364123A (en) * 1963-05-06 1968-01-16 Squibb & Sons Inc Production of 4n-demethyl-4n-ethyl tetracyclines
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
GB1065715A (en) * 1964-04-16 1967-04-19 Pfizer & Co C Tetracycline derivatives
US3247226A (en) * 1964-07-06 1966-04-19 American Cyanamid Co 4-dimethylamino and 4-hydroxytetracycloxides
US3394178A (en) * 1965-01-26 1968-07-23 Merck & Co Inc Nu-ethyloxytetracycline
GB1077598A (en) 1965-05-12 1967-08-02 Pfizer & Co C Preparation of n-demethyl tetracyclines
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
US3433709A (en) 1965-12-07 1969-03-18 American Cyanamid Co Biological transformation of alpha-6-deoxytetracyclines to tetracyclines
US3849493A (en) * 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3824285A (en) * 1967-09-13 1974-07-16 Pfizer 4-oxo-4-dedimethylaminotetracycline-4,6-hemiketals
US3947517A (en) 1969-06-12 1976-03-30 Research Corporation Stereoselective introduction of tetracyclines hydroxyl group at 12(a) position in synthesis of tetracyclines
DE2437487A1 (de) 1974-08-03 1976-02-19 Merck Patent Gmbh 7-methoxy-6-thia-tetracycline und verfahren zu ihrer herstellung
DE2442829A1 (de) * 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
YU290176A (en) * 1976-11-26 1982-05-31 Pliva Zagreb Process for preparing 4-dedimethylamino-4-arylsulfonamido-5a,6-anhydrotetracycline
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
ES2168254T3 (es) 1991-10-04 2002-06-16 American Cyanamid Co Nuevas 7-sustituidas-9-(amino sustituido)-6-desmetil-6-desoxitetraciclinas.
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
US5420272A (en) 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US5442059A (en) 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
EP0599397B1 (en) 1992-11-17 1996-08-28 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
AU1279095A (en) 1994-02-17 1995-09-04 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
US20020123637A1 (en) 1998-01-23 2002-09-05 Stuart B. Levy Pharmaceutically active compounds and methods of use thereof
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
CA2343038A1 (en) 1998-09-28 2000-04-06 Maria Emanuel Ryan A novel inhibitor of cataract formation
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
WO2001098260A1 (en) 2000-06-16 2001-12-27 Trustees Of Tufts College 7-n-substituted phenyl tetracycline compounds
CN1450989A (zh) 2000-07-07 2003-10-22 塔夫茨大学信托人 7－取代的四环素化合物
KR100674047B1 (ko) 2000-07-07 2007-01-25 트러스티즈 오브 터프츠 칼리지 9-치환된 미노사이클린 화합물
WO2002004404A2 (en) 2000-07-07 2002-01-17 Trustees Of Tufts College 7,8 and 9-substituted tetracycline compounds
IL157860A0 (en) 2001-03-13 2004-03-28 Paratek Pharm Innc 7,9-substituted tetracycline compounds
JP2005504722A (ja) 2001-03-14 2005-02-17 パラテック ファーマシューティカルズ インコーポレイテッド 相乗的抗真菌薬剤としての置換テトラサイクリン化合物
CA2457234A1 (en) 2001-03-14 2002-09-19 Mark L. Nelson Substituted tetracycline compounds as antifungal agents
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
CA2444899C (en) 2001-04-24 2011-06-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2332547A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of inflammatory bowel disease
EP2311798A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
WO2003075857A2 (en) 2002-03-08 2003-09-18 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
CA2479877C (en) 2002-03-21 2012-08-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2003261161B2 (en) 2002-07-12 2009-09-10 Paratek Pharmaceuticals, Inc 3, 10, and 12a substituted tetracycline compounds
JP2006503898A (ja) 2002-10-24 2006-02-02 パラテック ファーマシューティカルズ， インク． マラリア治療のための置換テトラサイクリン化合物
EP1562608A4 (en) 2002-10-24 2010-09-01 Paratek Pharm Innc METHOD OF USE OF SUBSTITUTED TETRACYCLINE COMPOUNDS FOR MODULATING THE RNA
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2005082860A1 (en) 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines and their use as calpain inhibitors
EP1753713B1 (en) 2004-05-21 2016-07-27 President and Fellows of Harvard College Synthesis of tetracyclines and analogues thereof
EP2301916A3 (en) 2004-10-25 2011-09-28 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2269978A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2597212A1 (en) 2005-02-04 2006-08-10 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
EP1848686A2 (en) 2005-02-15 2007-10-31 Wyeth 9-substituted tetracyclines
US20070093455A1 (en) 2005-07-21 2007-04-26 Paul Abato 10-substituted tetracyclines and methods of use thereof
EP2298324A1 (en) 2006-01-24 2011-03-23 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
EP2016044B1 (en) 2006-04-07 2020-06-10 President and Fellows of Harvard College Pentacycline derivatives for the treatment of infections
CA2652347A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
EP2479169B1 (en) 2006-10-11 2014-12-03 President and Fellows of Harvard College Synthesis of Enone Intermediate
IL270446B2 (en) 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
TWI334106B (en) 2006-12-27 2010-12-01 Icp Electronics Inc Apparatus for converting gray scale and method for the same
JP2010523684A (ja) 2007-04-12 2010-07-15 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物を用いる、脊髄筋委縮症を治療するための方法
EA201070233A1 (ru) 2007-07-06 2010-08-30 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
US7939513B2 (en) 2007-09-07 2011-05-10 Dr. Reddy's Laboratories Limited Tetracycline derivatives as antibacterial agents
JP2011517697A (ja) 2008-04-14 2011-06-16 パラテック ファーマシューティカルズ インコーポレイテッド 置換テトラサイクリン化合物
EP2307027A4 (en) * 2008-07-11 2012-08-15 Neumedics TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE PROPERTIES
CN105367440A (zh) 2008-08-08 2016-03-02 四相制药公司 C7-氟取代的四环素化合物
EP2424834B1 (en) 2009-04-30 2018-07-11 President and Fellows of Harvard College Synthesis of tetracyclines and intermediates thereof
CN102459153A (zh) * 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
ES2440000T3 (es) 2009-05-08 2014-01-27 Tetraphase Pharmaceuticals, Inc. Compuestos de 8-aza-tetraciclina
US20120115819A1 (en) 2009-05-13 2012-05-10 Clark Roger B Pentacycline Compounds
HUE037852T2 (hu) 2009-08-28 2018-09-28 Tetraphase Pharmaceuticals Inc Tetraciklin-vegyületek
WO2011109899A1 (en) 2010-03-10 2011-09-15 University Health Network Use of tigecycline for treatment of cancer
PL2552890T3 (pl) 2010-03-31 2017-07-31 Tetraphase Pharmaceuticals, Inc. Policykliczne związki tetracyklinowe
AR082633A1 (es) * 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
WO2012047907A1 (en) 2010-10-04 2012-04-12 President And Fellows Of Harvard College Synthesis of c5-substituted tetracyclines, uses thereof, and intermediates thereto
EA031523B1 (ru) * 2012-08-31 2019-01-31 Тетрафейз Фармасьютикалс, Инк. Тетрациклиновые соединения
MA40836A (fr) 2014-10-23 2017-08-29 Tetraphase Pharmaceuticals Inc Procédures de semi-synthèse
US10975029B2 (en) 2016-01-22 2021-04-13 Sandoz Ag Crystalline eravacycline bis-hydrochloride
JP7184756B6 (ja) 2016-08-30 2022-12-20 テトラフェース ファーマシューティカルズ，インコーポレイテッド テトラサイクリン化合物および処置方法
HRP20240605T1 (hr) 2016-10-19 2024-07-19 Tetraphase Pharmaceuticals, Inc. Kristalni oblici eravaciklina

Also Published As

Publication number Publication date
CA2883238C (en) 2021-11-23
IL266719A (en) 2019-07-31
NZ745596A (en) 2019-09-27
AU2013308504A1 (en) 2015-04-02
US20160107988A1 (en) 2016-04-21
NZ740051A (en) 2019-09-27
US10913712B2 (en) 2021-02-09
HUE042600T2 (hu) 2019-07-29
US9573895B2 (en) 2017-02-21
BR112015004523B1 (pt) 2020-08-04
SG11201501516YA (en) 2015-07-30
HRP20190268T1 (hr) 2019-05-03
US20170305852A1 (en) 2017-10-26
CN108276404A (zh) 2018-07-13
LT2890673T (lt) 2019-04-10
SG10201801703RA (en) 2018-04-27
EP3461809B1 (en) 2025-03-26
EP3461809A1 (en) 2019-04-03
AU2016247054B2 (en) 2018-08-09
CN104768922A (zh) 2015-07-08
NZ705849A (en) 2018-06-29
EA201891804A1 (ru) 2019-06-28
KR102295673B1 (ko) 2021-08-27
JP6691157B2 (ja) 2020-04-28
AU2016247054A1 (en) 2016-11-03
SMT201900096T1 (it) 2019-02-28
EA031523B1 (ru) 2019-01-31
CY1122744T1 (el) 2021-03-12
PL2890673T3 (pl) 2019-06-28
CA2883238A1 (en) 2014-03-06
KR102375238B1 (ko) 2022-03-15
KR20210107184A (ko) 2021-08-31
JP2015528468A (ja) 2015-09-28
US10315992B2 (en) 2019-06-11
MX364400B (es) 2019-04-24
JP2018118975A (ja) 2018-08-02
PT2890673T (pt) 2019-02-19
WO2014036502A3 (en) 2014-04-24
RS58572B1 (sr) 2019-05-31
DK2890673T3 (en) 2019-03-18
IL237437B (en) 2019-09-26
HK1211917A1 (en) 2016-06-03
US20200048193A1 (en) 2020-02-13
ME03329B (me) 2019-10-20
EA036088B1 (ru) 2020-09-25
MX2015002657A (es) 2015-05-20
JP6301335B2 (ja) 2018-03-28
EP2890673A2 (en) 2015-07-08
AU2013308504B2 (en) 2016-11-10
CN104768922B (zh) 2018-04-03
AU2017200857B2 (en) 2018-11-22
BR112015004523A2 (pt) 2017-07-04
CN108329312B (zh) 2021-12-31
WO2014036502A8 (en) 2014-07-31
ES2712476T3 (es) 2019-05-13
CN108329312A (zh) 2018-07-27
EP2890673B1 (en) 2018-11-14
SI2890673T1 (sl) 2019-05-31
TR201902057T4 (tr) 2019-03-21
EA201590475A1 (ru) 2016-05-31
KR20150065172A (ko) 2015-06-12
AU2017200857A1 (en) 2017-03-02
IL237437A0 (en) 2015-04-30
WO2014036502A2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
MX390763B (es) Compuestos de tetraciclina
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
NZ709211A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
MX368703B (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
MX358961B (es) Compuestos de tetraciclina sustituidos con fluor en c7.
MX2015018048A (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
IN2014MN02106A (es)
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
IN2014MN02598A (es)
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
EA201290632A1 (ru) Производные бетулина
MY187718A (en) Pharmaceutical formulations
WO2011123536A8 (en) Polycyclic tetracycline compounds
WO2010129057A3 (en) Tetracycline compounds
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
IN2012DN02502A (es)
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
IN2014CN04449A (es)